Guardant Health GH Stock
Guardant Health Price Chart
Guardant Health GH Financial and Trading Overview
| Guardant Health stock price | 39.97 USD |
| Previous Close | 38.01 USD |
| Open | 37.55 USD |
| Bid | 37.02 USD x 800 |
| Ask | 38.9 USD x 800 |
| Day's Range | 37.24 - 38.46 USD |
| 52 Week Range | 20.67 - 62.75 USD |
| Volume | 1.55M USD |
| Avg. Volume | 2.09M USD |
| Market Cap | 4.43B USD |
| Beta (5Y Monthly) | 0.799662 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54 USD |
GH Valuation Measures
| Enterprise Value | 4.32B USD |
| Trailing P/E | N/A |
| Forward P/E | -9.682864 |
| PEG Ratio (5 yr expected) | 0.43 |
| Price/Sales (ttm) | 9.19816 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 8.96 |
| Enterprise Value/EBITDA | -8.305 |
Trading Information
Guardant Health Stock Price History
| Beta (5Y Monthly) | 0.799662 |
| 52-Week Change | 1.96% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 62.75 USD |
| 52 Week Low | 20.67 USD |
| 50-Day Moving Average | 27.35 USD |
| 200-Day Moving Average | 36.56 USD |
GH Share Statistics
| Avg. Volume (3 month) | 2.09M USD |
| Avg. Daily Volume (10-Days) | 1.83M USD |
| Shares Outstanding | 117.14M |
| Float | 98.39M |
| Short Ratio | 2.48 |
| % Held by Insiders | 4.65% |
| % Held by Institutions | 92.24% |
| Shares Short | 6.93M |
| Short % of Float | 6.17% |
| Short % of Shares Outstanding | 5.91% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -137.90% |
| Operating Margin (ttm) | -115.99% |
| Gross Margin | 63.20% |
| EBITDA Margin | -107.88% |
Management Effectiveness
| Return on Assets (ttm) | -19.19% |
| Return on Equity (ttm) | -272.22% |
Income Statement
| Revenue (ttm) | 482.15M USD |
| Revenue Per Share (ttm) | 4.71 USD |
| Quarterly Revenue Growth (yoy) | 33.90% |
| Gross Profit (ttm) | 293.21M USD |
| EBITDA | -520179008 USD |
| Net Income Avi to Common (ttm) | -664892992 USD |
| Diluted EPS (ttm) | -7.09 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 937.02M USD |
| Total Cash Per Share (mrq) | 9.12 USD |
| Total Debt (mrq) | 1.37B USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.41 |
| Book Value Per Share (mrq) | -0.434 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -355284992 USD |
| Levered Free Cash Flow (ttm) | -328236736 USD |
Profile of Guardant Health
| Country | United States |
| State | CA |
| City | Palo Alto |
| Address | 3100 Hanover Street |
| ZIP | 94304 |
| Phone | 855 698 8887 |
| Website | https://guardanthealth.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 1793 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Q&A For Guardant Health Stock
What is a current GH stock price?
Guardant Health GH stock price today per share is 39.97 USD.
How to purchase Guardant Health stock?
You can buy GH shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Guardant Health?
The stock symbol or ticker of Guardant Health is GH.
Which industry does the Guardant Health company belong to?
The Guardant Health industry is Diagnostics & Research.
How many shares does Guardant Health have in circulation?
The max supply of Guardant Health shares is 123.89M.
What is Guardant Health Price to Earnings Ratio (PE Ratio)?
Guardant Health PE Ratio is now.
What was Guardant Health earnings per share over the trailing 12 months (TTM)?
Guardant Health EPS is -3.39 USD over the trailing 12 months.
Which sector does the Guardant Health company belong to?
The Guardant Health sector is Healthcare.
Guardant Health GH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19142.72 USD — |
-0.38
|
8.16B USD — | 19015.63 USD — | 19186.69 USD — | — - | 8.16B USD — |
| NASDAQ Global Select Market Com NQGS | 9365.63 USD — |
-0.4
|
— — | 9303.41 USD — | 9387.8 USD — | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2227.13 USD — |
+0.03
|
— — | 2216.57 USD — | 2233.85 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2999.52 USD — |
-0.31
|
— — | 2987.77 USD — | 3004.39 USD — | — - | — — |
| Nasdaq Next Generation 100 Inde NGX | 1261.61 USD — |
+0.06
|
— — | 1255.59 USD — | 1264.51 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4177.94 USD — |
+1.55
|
— — | 4103.9 USD — | 4188.28 USD — | — - | — — |
| Nasdaq Health Care IXHC | 955.99 USD — |
+0.93
|
— — | 944.04 USD — | 957.7 USD — | — - | — — |
- {{ link.label }} {{link}}